Literature DB >> 28855136

Ipratropium is 'luminally recycled' by an inter-play between apical uptake and efflux transporters in Calu-3 bronchial epithelial cell layers.

Vijender Panduga1, Michael J Stocks2, Cynthia Bosquillon3.   

Abstract

The mechanism by which quaternized anticholinergic bronchodilators permeate the airway epithelium remains controversial to date. In order to elucidate the role of drug transporters, ipratropium bidirectional transport as well as accumulation and release studies were performed in layers of the broncho-epithelial cell line Calu-3 grown at an air-liquid interface, in presence or absence of a range of transporter inhibitors. Unexpectedly, a higher transepithelial permeability was observed in the secretory direction, with an apparent efflux ratio of > 4. Concentration-dependent and inhibitor studies demonstrated the drug intracellular uptake was carrier-mediated. Interestingly, monitoring drug release post cell loading revealed the presence of an efficient efflux system on the apical side of the cell layers. Acting in concert, apical transporters seem to promote the 'luminal recycling' of the drug and hence, limit its transcellular transport. The data are in agreement with an apical Organic Cation Transporter (OCT) being involved in this process but also suggest the participation of unknown uptake and efflux transporters sensitive to probenecid. This study suggests the absorption of ipratropium across the pulmonary barrier is primarily governed by paracellular passive diffusion but transporters might play a significant role in controlling the drug local concentrations in the lungs.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carrier-mediated transport; Drug inhalation; Drug transporters; In vitro models; Muscarinic M3 receptor antagonists; Pulmonary drug delivery

Mesh:

Substances:

Year:  2017        PMID: 28855136     DOI: 10.1016/j.ijpharm.2017.08.112

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

2.  Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals.

Authors:  Tove Berg; Tove Hegelund-Myrbäck; Johan Öckinger; Xiao-Hong Zhou; Marie Brännström; Michael Hagemann-Jensen; Viktoria Werkström; Janeric Seidegård; Johan Grunewald; Magnus Nord; Lena Gustavsson
Journal:  Respir Res       Date:  2018-04-20

3.  Organic Cation Transporters (OCTs) in EpiAirway™, A Cellular Model of Normal Human Bronchial Epithelium.

Authors:  Amelia Barilli; Rossana Visigalli; Francesca Ferrari; Maria Di Lascia; Benedetta Riccardi; Paola Puccini; Valeria Dall'Asta; Bianca Maria Rotoli
Journal:  Biomedicines       Date:  2020-05-19

4.  Functional analysis of OCTN2 and ATB0,+ in normal human airway epithelial cells.

Authors:  Bianca Maria Rotoli; Rossana Visigalli; Amelia Barilli; Francesca Ferrari; Massimiliano G Bianchi; Maria Di Lascia; Benedetta Riccardi; Paola Puccini; Valeria Dall'Asta
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

Review 5.  Organic Cation Transporters in the Lung-Current and Emerging (Patho)Physiological and Pharmacological Concepts.

Authors:  Mohammed Ali Selo; Johannes A Sake; Carsten Ehrhardt; Johanna J Salomon
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

6.  Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.

Authors:  Nadica Sibinovska; Simon Žakelj; Jurij Trontelj; Katja Kristan
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.